CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 7, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,
Former CCO of Y-mAbs Therapeutics brings 20 years of pharma and biotech commercial leadership CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 5, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the
CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jan. 3, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,
